Aging, Arterial Stiffness, and Hypertension

Zhongjie Sun

Although the etiology of essential hypertension remains unknown, it is clear that multiple factors may contribute to the pathogenesis of hypertension. Hypertension is an outcome of the interaction of multiple genetic and environmental factors. Several epidemiological studies indicated that the incidence of arterial stiffness and hypertension and related cardiovascular disease (stroke, myocardial infarction) is higher in the aged than in the young population.1–4 The prevalence of arterial stiffening and hypertension increases with age.1,5 Based on an epidemiological study,6 the prevalence of hypertension is more than doubled in the elderly than in the young population. More than two-thirds of individuals after 65 years of age experience hypertension according to the Seventh Report of the Joint National Committee (JNC-7).7 Therefore, it is generally thought that hypertension is an aging disorder. In recent years, metabolic syndrome and hypertension are increasingly seen in the middle-aged and young populations. In these subpopulations, insulin resistance and overproduction of adipokines impair endothelial and heart function leading to early and accelerated cardiovascular aging. It was reported that premature aging (progeria) is associated with accelerated vascular stiffening or vascular aging.8

Aging is defined as the age-related decline in physiological function essential for survival and fertility. Cardiovascular aging is an important factor that determines life span. The wall of large conduit arteries, especially aorta, thicken and lose elasticity over time, and this process results in an increase in pulse wave velocity, an important and reliable measure of arterial stiffness. The increased arterial stiffness, whatever its underlying causes, would reduce the reservoir/buffering function of the conduit arteries near the heart and increase pulse wave velocity, both of which increase systolic and pulse pressure. Therefore, aging-related hypertension is characterized by a significant increase in systolic blood pressure with no change or even a decrease in diastolic blood pressure, namely isolated systolic hypertension. Age is an important determinant of pulse wave velocity.9 Arterial stiffening is an independent predictor of cardiovascular outcomes, such as myocardial infarction, cognitive decline in aging, stroke, and kidney diseases.10–12 In a longitudinal community-based cohort study conducted in Framingham, Massachusetts, Kaess et al13 showed that increased aortic stiffness and augmentation are associated with higher risk of incident hypertension. However, initial blood pressure is not independently associated with the risk of progressive aortic stiffening. Therefore, arterial stiffness predicts an increase in systolic blood pressure and incident hypertension.13 These observations indicate a close relationship between aortic stiffening and the development of hypertension in human subjects. A recent report indicates that arterial stiffening precedes the development of hypertension in an animal model of high-fat diet–induced hypertension.14 Current antihypertensive drugs were mainly designed to reduce peripheral resistance and are not adequate to alter the pathological process of vascular stiffening or even selectively reducing systolic blood pressure in isolated systolic hypertension. This review updates the recent advances in the mechanism of aging-related arterial stiffening and hypertension based on the articles published in Hypertension in the past 2 to 3 years.

Metabolic Syndrome Contributes to Aging-Related Arterial Stiffening and Hypertension

With aging, the prevalence of metabolic syndrome, an important risk factor for cardiovascular disease, is increased although the underlying mechanism is not fully understood. Metabolic syndrome is defined by ≥3 of the following characteristics: abnormal obesity, dyslipidemia, hypertension, insulin resistance, and hyperglycemia. Age induces an increase in visceral fat and circulating leptin, which is associated with a significant increase in blood pressure.15 Numerous studies indicated that metabolic syndrome promotes arterial stiffening and accelerates vascular aging and development of hypertension in humans.5,16–18 A recent report showed that body fat is associated with reduced arterial stiffening until middle age,19 indicating that the vascular system may be capable of adapting to obesity and that an adverse association between body fat and arterial stiffening only seems in later life. Therefore, aging may promote metabolic syndrome–induced arterial stiffening (Figure). A longitudinal study showed that clustering of metabolic syndrome–induced arterial stiffening is associated with maladaptive carotid remodeling and stiffening.20 Notably, a recovery from the metabolic syndrome restored carotid properties to normal levels, indicating that metabolic syndrome–induced arterial remodeling and stiffening are reversible.17 In an animal model of diet-induced obesity, normalization of the metabolic state by weight loss leads to a return of arterial stiffness and high blood pressure to

Hypertension is available at http://hyper.ahajournals.org

DOI: 10.1161/HYPERTENSIONAHA.114.03617
Inflammation Mediates Aging-Related Arterial Stiffening and Hypertension

Inflammation is increased with aging. An increase in inflammatory cytokines and chemokines leads to infiltrations of T cells and macrophages, which could cause tissue injury. Overactive sympathetic nervous system causes inflammatory responses. Aging is associated with elevated sympathetic nervous activity,23 which may contribute to increased inflammation in aging.22 Aldosterone is known to cause inflammatory responses and T-cell infiltration. Aging is associated with dysregulation of aldosterone,24 which may play a role in aging-related inflammation. It has been reported that metabolic syndrome is linked to increased inflammation (Figure).25,26 Obesity is associated with chronic inflammatory responses, including abnormal adipokine production, increased release of proinflammatory cytokines and chemokines, and macrophage and lymphocyte infiltration.26 These inflammatory responses in adipose tissue may contribute to the pathogenesis of obesity and obesity-induced vascular endothelial dysfunction and arterial stiffening. T-regulatory lymphocytes suppress inflammatory responses and attenuate hypertension-associated organ damage. It was reported that high-fructose diet–induced metabolic syndrome decreased the number and function of the T-regulatory lymphocytes,27 which may promote metabolic syndrome–associated arterial stiffening and hypertension.

The mechanistic role of immune activation and inflammation in the pathogenesis of hypertension is increasingly appreciated based on a recent comprehensive review.28 Several reports indicate that autoimmunity and inflammation may be associated with hypertension.29,29 Anti-CD20 antibody treatment prevents the development of hypertension in a mouse model of lupus.29 Anti-CD20 antibody blunts the upregulation of tumor necrosis factor-α and monocyte chemotacti protein-1 in renal cortices and attenuates the increase in circulating T cells in mice with lupus, contributing to the antihypertensive effect of anti-CD20.29 This study also suggests a new and interesting role of autoantibody in regulating cytokine release and T-cell migration although the mechanistic link remains to be resolved. Cold exposure causes pulmonary hypertension that is preceded by the upregulation of tumor necrosis factor-α in pulmonary arteries and lungs.30 RNA interference inhibition of tumor necrosis factor-α prevents infiltration of T cells and macrophages and attenuates cold-induced pulmonary hypertension and pulmonary arterial remodeling,30 suggesting that tumor necrosis factor-α is a critical cytokine that initiates cold-induced pulmonary vascular damage. It has been shown that T-cell infiltration and inflammation are involved in angiotensin II–induced hypertension and vascular dysfunction.28 Genetic deletion of T cells (RAG-2) prevents angiotensin II–induced hypertension, suggesting an important role of T cells in this model of hypertension.28 Inflammation and mechanical stretch promote collagen deposition and arterial stiffening via activation of p38 mitogen-activated protein kinase.31 A recent study showed that cardiotrophin 1, a cytokine of the interleukin-6 family, may be involved in aging-related arterial stiffening.32 Cardiotrophin 1 is a potent fibrotic factor in heart, vessels, and kidneys.33 Genetic deletion of cardiotrophin 1 leads to decreased arterial fibrosis, stiffness, and senescence and increases life span (longevity) in aging.
mice likely via downregulation of apoptosis and inflammatory pathways. Therefore, inflammation may play a critical role in aging-related vascular remodeling, arterial stiffening, and hypertension (Figure) although the underlying mechanism remains to be determined.

**Neurohumoral Dysfunction Plays a Role in Aging-Related Vascular Dysfunction and Hypertension**

The autonomic nervous system is critical in the regulation of peripheral resistance and blood pressure. Metabolic syndrome is associated with increased sympathetic overactivity. Insulin resistance and dysregulated adipokine production in obesity-related metabolic syndrome lead to sympathetic activation contributing to metabolic syndrome–induced hypertension. The sympathetic nervous activity is positively associated with arterial blood pressure in women after menopause. The autonomic support of arterial blood pressure is greater in older women than that in young women. The sympathetic nerve activity is elevated in older women, which contributes to the increased incidence of hypertension in aging women. The aging-associated increase in sympathetic activity is likely because of blunted baroreflex sensitivity. Large artery stiffness (carotid artery and aortic arch) is associated with an age-related decrease in sympathetic baroreflex sensitivity in elderly men and women. This is mainly because of changes in the mechanical property (eg, loss of elasticity) of the large baroreceptive arteries as a result of stiffening. The diminished sympathetic baroreflex sensitivity in the elderly leads to sympathetic activation and increased prevalence of hypertension in the aged population (Figure). Increased inflammation in brain stem (eg, nucleus tractus solitarii) is causally associated with neurogenic hypertension. It was reported that senescence-associated brain structural and functional deterioration may also contribute to aging-related autonomic dysfunction (eg, elevated sympathetic activity) and hypertension.

It is known that salt sensitivity and vascular endothelial dysfunction are increased in the aging population (Figure). Salt intake is one of the main environmental factors contributing to the development of hypertension. Salt sensitivity is more common in the old than in the young population. The relationship of age and salt sensitivity seems to be stronger in hypertensive individuals. Recent studies suggested that overactivation of the innate or adaptive immune system leads to renal inflammation that contributes to salt sensitivity. Functional T cells are required for the development of Dahl salt-sensitive hypertension. Inhibition of T-cell and macrophage infiltration in kidneys attenuates high salt–induced hypertension in mice with haploinsufficiency of an antiaging gene klotho. Therefore, aging-related salt sensitivity may be mediated by increased inflammation. Interestingly, the vascular endothelial expression of sodium channel increases with age. Spironolactone and amiloride decreased endothelial expression of sodium channel abundance and prevented endothelial stiffening in aging mice. Therefore, upregulation of endothelial expression of sodium channel mediates aging-associated endothelial salt sensitivity, which contributes to vascular stiffening in aging. Aging is also associated with dysregulation of aldosterone and its receptors, which impair vascular function leading to vascular remodeling and hypertension.

Aging-related endothelial dysfunction and the resultant vascular remodeling and stiffening may be because of decreased nitric oxide (NO) bioavailability because of endothelial nitric oxide synthase dysfunction and endothelial nitric oxide synthase uncoupling. Short-term treatment with a lipid-lowering agent fenofibrate improves endothelium-dependent vasodilation in older adults by reducing oxidative stress and increasing endothelial nitric oxide synthase. A decrease in NO leads to decreased intracellular cyclic guanosine monophosphate levels, contributing to arterial remodeling. Upregulation of phosphodiesterases that decomposes cyclic guanosine monophosphate also decreases intracellular cyclic guanosine monophosphate levels. Inhibition of phosphodiesterase 5 increases bioavailability of intracellular cyclic guanosine monophosphate, which results in vasodilation and attenuation of hypertension and kidney damage. It was recently reported that upregulation of phosphodiesterase 1C may be involved in cold-induced pulmonary hypertension and pulmonary arterial remodeling. Inhibition of PDE1 eliminated cold-induced macrophage infiltration, NADPH oxidase activation, and superoxide production and reversed pulmonary arterial remodeling.

**Aging-Related Genes and Hypertension: A Perspective**

Aging is an independent risk factor for arterial stiffness and hypertension. Arterial stiffening and hypertension are aging-related disorders. Therefore, it would be interesting to assess whether antiaging treatment slows and attenuates vascular dysfunction and hypertension. Klotho gene was identified as an aging-suppressor gene that extends life span when overexpressed and shortens life span when disrupted. In humans, the prevalence of hypertension increases with age while the klotho level declines with age after the age of 40 years. High levels of klotho are independently associated with lower likelihood of having hypertension and related cardiovascular disease. The development and progression of genetic hypertension are also age-dependent in spontaneous hypertensive rats. In spontaneous hypertensive rats, klotho gene expression was downregulated while blood pressure is elevated. Interestingly, in vivo expression of klotho gene prevented progression of hypertension and abolished kidney damages in spontaneous hypertensive rats, suggesting that klotho may be involved in the pathogenesis of spontaneous hypertension. In vivo expression of klotho abolished the downregulation of IL-10, an anti-inflammatory cytokine, and the upregulation of Nox2 expression, NADPH oxidase activity, and superoxide production in aortas and kidneys of spontaneous hypertensive rats. These findings suggest that antiaging gene klotho protects against cardiovascular aging via inhibition of inflammation and oxidative stress. It seems equally important to assess whether disruption of antiaging gene klotho affects blood pressure. In a recent study, Zhou et al demonstrated that haploinsufficiency of klotho gene (+/−) causes spontaneous and persistent hypertension in mice. Blood pressure starts to elevate spontaneously ≈16 to 17 weeks of age. Interestingly, the high-salt intake further increases blood pressure and exacerbates hypertension in KL(+/−) mice.
indicating that KL deficiency elicited salt-sensitive hypertension. The high-salt loading causes inflammation as evidenced by increased expression of MCP-1 and infiltration of macrophages and T cells in kidneys in KL(+/−) mice. Blockade of CC chemokine receptor 2 abolishes the high-salt–induced increase in blood pressure in KL(+/−) mice, suggesting an important role of monocyte chemotaxis in klotho deficiency–induced salt-sensitive hypertension. It would be interesting to assess whether klotho deficiency may be involved in aging-related arterial stiffening.

Because the mechanism of aging-related arterial stiffening and hypertension includes metabolic syndrome, inflammation, and neurohormonal dysfunction (Figure), effective control of these aging-accelerating factors would benefit the cardiovascular system and extend the life span. Some other aging-related genes such as sirtuins (eg, Sirt1 demethylase) and mTOR (mammalian target of rapamycin) have been shown to be involved in the regulation of vascular endothelial function and life span. Their roles in the development of arterial stiffening and hypertension need to be investigated.

Sources of Funding
This work was supported by the National Institute of Health (NIH), R01 HL105302, HL102074, HL118558, HL116863, and DK 093403.

Disclosures
None.

References


Aging, Arterial Stiffness, and Hypertension
Zhongjie Sun

Hypertension. 2015;65:252-256; originally published online November 3, 2014;
doi: 10.1161/HYPERTENSIONAHA.114.03617
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://hyper.ahajournals.org/content/65/2/252

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about
this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/